Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma

Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors

(2011) Shuichiro Shiina et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database

(2011) Tania M. Welzel et al.   HEPATOLOGY

Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?

(2011) Etsuko Hashimoto et al.   HEPATOLOGY RESEARCH

Recent trend of clinical features in patients with hepatocellular carcinoma

(2011) Yuko Nagaoki et al.   HEPATOLOGY RESEARCH

Clinical and Prognostic Implications of Plasma Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Patients With Hepatocellular Carcinoma

(2011) Ahmed O. Kaseb et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

(2011) Pierre-Alain Clavien et al.   LANCET ONCOLOGY

Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis

(2010) Judith Ertle et al.   INTERNATIONAL JOURNAL OF CANCER

Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?

(2010) Fidel-David Huitzil-Melendez et al.   JOURNAL OF CLINICAL ONCOLOGY

Metabolic syndrome and hepatocellular carcinoma

(2009) Abby B. Siegel et al.   CANCER

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis

(2009) Valérie Paradis et al.   HEPATOLOGY

Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics

(2009) Mohamed IF Shariff et al.   Expert Review of Gastroenterology & Hepatology

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE